Quarterly report [Sections 13 or 15(d)]

Segment Reporting (Tables)

v3.25.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Summary of Operating Costs and Expenses and Interest Expense, Net

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Product Revenue, net

 

$

390

 

 

$

—

 

 

$

390

 

 

$

—

 

Segment cost of sales

 

 

(20

)

 

 

—

 

 

 

(20

)

 

 

—

 

Amortization of intangible asset (a)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Segment research and development (b) (c)

 

 

(1,244

)

 

 

(3,077

)

 

 

(2,795

)

 

 

(8,998

)

Segment selling, general and administration (b) (c)

 

 

(6,449

)

 

 

(1,734

)

 

 

(13,320

)

 

 

(5,731

)

Share-based compensation expense (see Note 15)

 

 

(53

)

 

 

(68

)

 

 

(170

)

 

 

(274

)

Depreciation and amortization

 

 

(355

)

 

 

(8

)

 

 

(1,055

)

 

 

(23

)

Operating loss

 

$

(7,731

)

 

$

(4,887

)

 

$

(16,970

)

 

$

(15,026

)

 

a)
Amortization expense of $349 and $1,036 related to the Pfizer Intangible Asset has been excluded for the three and nine months ended September 30, 2025, respectively, and included within depreciation and amortization.
b)
Share-based payment expense of $15 and $50 related to research and development and $38 and $120 related to general and administration have been excluded for the three and nine months ended September 30, 2025, respectively, and included within share-based compensation expense. Share-based payment expense of $25 and $147 related to research and
development and $43 and $127 related to general and administration have been excluded for the three and nine months ended September 30, 2024, respectively, and included within share-based compensation expense.
c)
Depreciation expense of $2 and $7 related to research and development and $4 and $12 related to general and administration have been excluded for the three and nine months ended September 30, 2025, respectively, and included within depreciation and amortization. Depreciation expense of $5 and $14 related to research and development and $3 and $9 related to general and administration have been excluded for the three and nine months ended September 30, 2024, respectively, and included within depreciation and amortization.

Interest Expense, Net

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Interest income

 

$

121

 

 

$

166

 

 

$

406

 

 

$

607

 

Interest expense

 

 

(562

)

 

 

(756

)

 

 

(1,697

)

 

 

(2,255

)

Interest expense, net

 

$

(441

)

 

$

(590

)

 

$

(1,291

)

 

$

(1,648

)
Schedule of Distribution of Long-Lived Assets by Geographical Area

The distribution of long-lived assets by geographical area was as follows:

Long-lived assets

 

September 30, 2025

 

 

December 31, 2024

 

Ireland

 

$

18,736

 

 

$

19,759

 

U.S.

 

 

11

 

 

 

15

 

Total

 

$

18,747

 

 

$

19,774